Received Oct 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
neuropathy vasculitis; This is a spontaneous report and received from Consumer or other non HCPs from medical information team, Program ID. A female patient received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications and included unspecified blood thinners. On an unspecified date, the patient experienced from neuropathy vasculitis and began shortly after she received the Pfizer Comirnaty vaccines. The reporter strongly believes there is a connection between the vaccine and the diagnosis. He expressed a desire to know whether Pfizer is aware of this as a side effect and how many patients have been affected by this. And, if so, what can be done to treat or possibly reverse it. He acknowledged that no one has a clear finger to point with 100% confidence in the connection, but there is a strong likelihood of a suspected connection. Other professionals have also correlated the COVID vaccine with his mother's condition, especially considering her current and previous medical history of being on blood thinners, which may have contributed to the condition in combination with the vaccine. He suggested that this could be an uncharted area or something not publicized. He shared that his mother is in daily, constant pain due to nerve conditions and can barely walk. The condition has had a negative impact and affects the entire family. Since the onset, they have been consulting various medical professionals, who remain puzzled. She has been referred to every department and even undergone cancer treatment reviews to explore possible solutions. Outcome of the event was not recovered. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.